Effect of Konjac-mannan in Individuals With Insulin-Resistance Syndrome

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Insulin Resistance Syndrome Clinical Trial

Official title:
Beneficial Effects of Viscous Dietary Fiber From Konjac-Mannan in Subjects With the Insulin Resistance Syndrome

Status Completed

Clinical Trial Summary

To study whether a diet high in fiber from Konjac-mannan (KJM) has an effect on metabolic control in individuals with insulin resistance syndrome.

n/a

NCT number	NCT03741686
Study type	Interventional
Source	St. Michael's Hospital, Toronto
Contact
Status	Completed
Phase	Phase 2
Start date	January 1991
Completion date	June 1999

See also
Status	Clinical Trial	Phase
Terminated	`NCT04028895` - Diagnostic Interest of the IRAP Protein (Insulin Regulated Amino Peptidase) in Insulin Resistance	N/A
Active, not recruiting	`NCT04018365` - A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance	Phase 3
Completed	`NCT03011775` - Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease	Phase 4
Completed	`NCT03716336` - Aerobic and Strength Training With Caloric Restriction on Insulin Resistance in Obese Premenopausal Women	N/A
Recruiting	`NCT04128969` - Causal Mechanisms in Adolescent Arterial Stiffness	Phase 2
Active, not recruiting	`NCT04221152` - A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )	Phase 3